Nathan A. M. Dunn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nathan A. M. Dunn has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- David Wyld
Royal Brisbane and Women’s Hospital
1 shared publication - James M. McGree
School of Mathematical Sciences, Queensland University of Technology, GPO Box 2344, Brisbane, QLD 4001, Australia
1 shared publication - Jeff Ching-Fu Hsieh
Mathematical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.
1 shared publication - Julie Moore
Cancer Alliance Queensland, Metro South Hospital and Health Service, 2 Burke St, Woolloongabba, Qld, 4102, Australia
1 shared publication - Kerrie Mengersen
School of Mathematical Sciences, Queensland University of Technology, Brisbane, Australia; Centre for Data Science (CDS), Queensland University of Technology (QUT), Brisbane, Australia
1 shared publication Mark H. Wan
Faculty of Medicine, The University of Queensland, 288 Herston Road, Herston, Qld, 4006, Australia
1 shared publication
Latest Publications
- 1 December 2019
- Published by Elsevier in Cancer Epidemiology
- Vol. 63, 101598
Epidemiological trends of neuroendocrine tumours over three decades in Queensland, Australia
- 1 December 2019
- Published by Elsevier in Cancer Epidemiology
- Vol. 63, 101598
Epidemiological trends of neuroendocrine tumours over three decades in Queensland, Australia
- Open Access
- 2 December 2015
- Published by Springer Nature in BMC Public Health
- Vol. 15 (1) , 1-17
Geographic variation in the intended choice of adjuvant treatments for women diagnosed with screen-detected breast cancer in Queensland
Although early diagnosis and improved treatment can reduce breast cancer mortality, there still appears to be a geographic differential in patient outcomes. This study aims to determine and quantify spatial inequalities in intended adjuvant (radio-, chemo- and hormonal) therapy usage among women with screen-detected breast cancer in Queensland, Australia. Linked population-based datasets from BreastScreen Queensland and the Queensland Cancer Registry during 1997−2008 for women aged 40−89 years were used. We adopted a Bayesian shared spatial component model to evaluate the relative intended use of each adjuvant therapy across 478 areas as well as common spatial patterns between treatments. Women living closer to a cancer treatment facility were more likely to intend to use adjuvant therapy. This was particularly marked for radiotherapy when travel time to the closest radiation facility was 4 + h (OR =0.41, 95 % CrI: [0.23, 0.74]) compared to <1 h. The shared spatial effect increased towards the centres with concentrations of radiotherapy facilities, in north-east (Townsville) and south-east (Brisbane) regions of Queensland. Moreover, the presence of residual shared spatial effects indicates that there are other unmeasured geographical barriers influencing women’s treatment choices. This highlights the need to identify the additional barriers that impact on treatment intentions among women diagnosed with screen-detected breast cancer, particularly for those women living further away from cancer treatment centers.
- 2 December 2015
- Published by Springer Nature in BMC Public Health
- Vol. 15 (1) , 1-17
Open AccessGeographic variation in the intended choice of adjuvant treatments for women diagnosed with screen-detected breast cancer in Queensland
Although early diagnosis and improved treatment can reduce breast cancer mortality, there still appears to be a geographic differential in patient outcomes. This study aims to determine and quantify spatial inequalities in intended adjuvant (radio-, chemo- and hormonal) therapy usage among women with screen-detected breast cancer in Queensland, Australia. Linked population-based datasets from BreastScreen Queensland and the Queensland Cancer Registry during 1997−2008 for women aged 40−89 years were used. We adopted a Bayesian shared spatial component model to evaluate the relative intended use of each adjuvant therapy across 478 areas as well as common spatial patterns between treatments. Women living closer to a cancer treatment facility were more likely to intend to use adjuvant therapy. This was particularly marked for radiotherapy when travel time to the closest radiation facility was 4 + h (OR =0.41, 95 % CrI: [0.23, 0.74]) compared to <1 h. The shared spatial effect increased towards the centres with concentrations of radiotherapy facilities, in north-east (Townsville) and south-east (Brisbane) regions of Queensland. Moreover, the presence of residual shared spatial effects indicates that there are other unmeasured geographical barriers influencing women’s treatment choices. This highlights the need to identify the additional barriers that impact on treatment intentions among women diagnosed with screen-detected breast cancer, particularly for those women living further away from cancer treatment centers.